fibrinopeptide-a and Kidney-Failure--Chronic

fibrinopeptide-a has been researched along with Kidney-Failure--Chronic* in 13 studies

Reviews

1 review(s) available for fibrinopeptide-a and Kidney-Failure--Chronic

ArticleYear
Equivalent effective doses of heparin and low molecular weight heparin(oid)s in haemodialysis for chronic renal failure.
    Acta chirurgica Scandinavica. Supplementum, 1988, Volume: 543

    In an attempt to provide an objective means of comparing the anticoagulant action of heparin with those of newly developed low MW heparin-like anticoagulants we have utilized the fibrinpeptide A assay as a method of determining fibrin formation during haemodialysis. In vivo suppression of FPA levels by increasing doses of administered anticoagulant enables equivalent effective doses of anticoagulants to be determined without making prior assumptions about which ex vivo activities of these compounds are responsible. In this communication we summarize results of studies with heparin and three low MW heparin(oid)s.

    Topics: Blood Coagulation; Fibrinopeptide A; Heparin; Heparin, Low-Molecular-Weight; Humans; Kidney Failure, Chronic; Renal Dialysis

1988

Trials

4 trial(s) available for fibrinopeptide-a and Kidney-Failure--Chronic

ArticleYear
Standard heparin versus low-molecular-weight heparin. A medium-term comparison in hemodialysis.
    Nephron, 2002, Volume: 92, Issue:3

    To compare standard heparin (SH) and low molecular weight heparin (LMWH) in terms of anticoagulation, platelet activation and lipid metabolism, we selected 54 patients who had been on 4-hour hemodialysis three times weekly for at least 12 months, without bleeding disorders or dyslipidemic diseases. 28 were on hemodialysis with Polysulfone low-flux, 26 were on hemodiafiltration with Polysulfone high-flux. All patients underwent EPO.. During the first 18 months, we administered SH 1,500 IU on starting dialysis and 1,500 +/- 500 IU in continuous intradialytic infusion per session. In the following 18 months, we administered LMWH 64.6 IU/kg on starting dialysis in a single arterious bolus. We assessed aPTT, anti-factor Xa activity, TAT and FPA, beta-TG and PF4. Blood samples were taken monthly at times 0, 30, 60, 180 and 240 min, as well as 1, 4 and 20 h after dialysis end. Predialysis cholesterol, HDL, LDL, triglycerides and lipoprotein(a) were checked monthly.. During both LMWH and SH sessions no clotting or major bleeding complications were observed. APTT with LMWH was lower than that found with SH (p < 0.001); aFXa using LMWH was higher than when using SH (p < 0.001); TAT and FPA were lower in LMWH sessions (p < 0.01) than in SH sessions. We also detected lower beta-TG (p < 0.05) and PF4 levels (p < 0.05) using LMWH than using SH. As regards lipids, we only observed a significant decrease in triglycerides after 18 months of LMWH treatment.. Routine use of LMWH during hemodialysis affords a safe and effective alternative to SH, and causes reduced platelet activation.

    Topics: Aged; Anticoagulants; Antithrombin III; beta-Thromboglobulin; Blood Coagulation; Cross-Over Studies; Factor Xa; Factor Xa Inhibitors; Female; Fibrinopeptide A; Hemodiafiltration; Heparin; Heparin, Low-Molecular-Weight; Humans; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Partial Thromboplastin Time; Peptide Hydrolases; Platelet Activation; Platelet Factor 4; Renal Dialysis

2002
Antithrombotic properties of dermatan sulphate (MF 701) in haemodialysis for chronic renal failure.
    Thrombosis and haemostasis, 1992, Nov-10, Volume: 68, Issue:5

    The therapeutic potential of the glycosaminoglycan (GAG), dermatan sulphate (DS), as an antithrombotic agent in humans has yet to be established. We have performed dose ranging studies of DS to determine its effectiveness as an antithrombotic agent in patients (n = 6-8) undergoing haemodialysis for chronic renal failure. In an initial study, Study 1, i.v. bolus doses of 2-4 mg/kg and 5-6 mg/kg DS were given to patients dialysing with polyacrylonitrile hollow fibre (PAN HF) membranes. In a second crossover study, Study 2, performed using cuprophane hollow fibre (CHF) membranes, i.v. bolus doses of 3 mg/kg and 6 mg/kg DS were compared to a standard unfractionated heparin (UFH) regime that has been shown previously to inhibit fibrin formation. Further infusion studies, Study 3 and Study 4 evaluated the antithrombotic efficacy of an i.v. DS bolus of 3 mg/kg plus an i.v. infusion of DS 0.6 mg kg-1 h-1 and a DS bolus of 5 mg/kg plus an infusion of 1 mg kg-1 h-1 over 5 h, respectively. These studies were compared to standard UFH regimes in a randomised crossover design. Plasma levels of fibrinopeptide A (FPA) and thrombin-antithrombin (TAT) were used as markers of fibrin formation and thrombin generation during dialysis using both membranes. The changes in DS concentration following administration of the different doses were similar in Studies 1 and 2. However, the effectiveness of DS as an anticoagulant appeared to depend markedly on the different dialyser types used in the two studies.(ABSTRACT TRUNCATED AT 250 WORDS)

    Topics: Adult; Aged; Aged, 80 and over; Antithrombin III; Blood Coagulation; Dermatan Sulfate; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents; Fibrinopeptide A; Heparin; Humans; Kidney Failure, Chronic; Male; Middle Aged; Peptide Hydrolases; Renal Dialysis; Thrombosis

1992
Dose finding study of a low molecular weight heparin, Innohep, in haemodialysis.
    Thrombosis and haemostasis, 1991, Sep-02, Volume: 66, Issue:3

    A pilot investigation was performed with Innohep, a low molecular weight (LMWH) preparation (peak maximum molecular mass 3,000-6,000), to determine possible dose regimens for patients undergoing regular maintenance haemodialysis for chronic renal failure. Results from this study suggested that suppression of macroscopic clot formation and fibrinopeptide A (FPA), a marker of fibrin formation, could be achieved following bolus injections rather than bolus injections and an infusion. On the basis of these preliminary findings, a randomised crossover study was performed in eight patients undergoing regular maintenance haemodialysis for 5-7 h to determine the effective antithrombotic dose of this LMWH. Single i.v. bolus doses of 1,250 AFXa u, 2,500 AFXa u and 5,000 AFXa u (n = 7-8) were compared to an UFH regime of 5,000 iu + 1,500 iu/h. Excessive clot formation in the dialyser bubble trap, necessitating additional UFH to enable completion of a prolonged (up to 7 h) dialysis, was observed in all patients on the 1,250 AFXa u dose (mean duration of dialysis prior to UFH, 3 h) but in a single patient only receiving the other LMWH doses. A dose-related response in the AFXa activity, measured by chromogenic substrate (CS) assay was seen in the three LMWH groups, with levels declining significantly (p less than 0.05) from 1-7 h. This contrasted with the constant levels maintained during dialysis with UFH. FPA levels were significantly elevated after 2 h following the 1,250 AFXa u bolus and after 4 h following the 2,500 AFXa u bolus. There was no significant difference in FPA levels between the 5,000 AFXa u bolus and UFH.(ABSTRACT TRUNCATED AT 250 WORDS)

    Topics: Dose-Response Relationship, Drug; Fibrinopeptide A; Heparin; Humans; Kidney Failure, Chronic; Molecular Weight; Monitoring, Physiologic; Pilot Projects; Renal Dialysis; Thromboembolism

1991
Hemodialysis and heparin. Alternative methods of measuring heparin and of detecting activation of coagulation.
    Clinical nephrology, 1991, Volume: 35, Issue:1

    A bolus dose of heparin was administered pre-dialysis to patients (n = 6) undergoing regular maintenance hemodialysis with cuprophane flat plate and hollow fiber membranes. Blood samples were withdrawn at hourly internals for measurement of a) heparin and b) activation markers of coagulation, fibrinolysis and platelets. Two assay methods for heparin were employed; amidolytic assay of anti-factor Xa activity in plasma and a simple whole blood clotting time based upon factor Xa inhibition (Heptest). Results from these heparin assays correlated well with each other (r = 0.89) and both showed similar negative correlations (r = -0.72, amidolytic and r = -0.66, Heptest) with levels of a marker of fibrin clot formation, fibrinopeptide A (FPA). Large differences in levels of FPA were observed during dialysis with the two dialyzer types, when similar levels of heparin were present. Heparin levels declined from 1-5-h dialysis and were associated with rises in plasma levels of FPA, thrombin-antithrombin complex (TAT) and beta thromboglobulin (BTG), but not of D-dimer. Regression analysis revealed the best correlation was between FPA and TAT (r = 0.94), followed by FPA and BTG (r = 0.81). FPA and D-dimer exhibited significant, but lower (r = 0.42), correlation. TAT levels, like FPA levels, showed good correlation with heparin (r greater than 0.65). It is concluded that the Heptest assay may be a useful bedside measurement of heparin levels and the TAT assay may be a simplified means of evaluating coagulation system activation during dialysis.

    Topics: Antithrombin III; beta-Thromboglobulin; Biomarkers; Factor Xa; Fibrin Fibrinogen Degradation Products; Fibrinolysis; Fibrinopeptide A; Heparin; Humans; Kidney Failure, Chronic; Peptide Hydrolases; Platelet Aggregation; Renal Dialysis; Whole Blood Coagulation Time

1991

Other Studies

8 other study(ies) available for fibrinopeptide-a and Kidney-Failure--Chronic

ArticleYear
Effective anticoagulation by a low molecular weight heparin (Fragmin) in hemodialysis with a highly permeable polysulfone membrane.
    Clinical nephrology, 1992, Volume: 38, Issue:2

    The efficacy and kinetics of a low molecular weight heparin fragment (LMWH-fragment, Fragmin) were studied during one hemodialysis session with a highly permeable polysulfone membrane and compared to a second dialysis session using a conventional cuprophane membrane. All patients received 5000 U of Fragmin given as an injection into the arterial line at start of dialysis. The anticoagulative efficacy was evaluated by measuring plasma fibrinopeptide A concentrations. LMWH-fragment concentrations in plasma and ultrafiltrate were determined by an amidolytic activity assay and by a radioimmunoassay using a monoclonal antibody. During hemodialysis with cuprophane and polysulfone membranes the fibrinopeptide A concentrations were low indicating adequate anticoagulation. LMWH concentrations in plasma did not differ in the two membranes at any time. The LMWH-fragment in the ultrafiltrate could neither be detected with the amidolytic assay nor with the radioimmunoassay. We conclude that a single injection of Fragmin effectively prevents clotting during hemodialysis with a highly polysulfone membrane. No significant amounts of the anticoagulant are lost over the dialysis membrane.

    Topics: Aged; Biocompatible Materials; Cellulose; Female; Fibrinopeptide A; Heparin, Low-Molecular-Weight; Humans; Kidney Failure, Chronic; Male; Membranes, Artificial; Middle Aged; Polymers; Renal Dialysis; Sulfones

1992
Autoantibody to plasma fibrinopeptide A in a patient with a severe acquired haemorrhagic syndrome.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 1992, Volume: 3, Issue:5

    We describe a 50-year-old man with a severe acquired haemorrhagic syndrome. He had slightly prolonged clotting times using bovine thrombin, human thrombin and reptilase. His plasma contained a polyclonal IgG which interfered with the generation of fibrin monomers without inhibiting the aggregation of preformed monomers. The inhibitor delayed thrombin-induced fibrinopeptide A release. The IgG bound to insolubilized synthetic fibrinopeptide A (one binding site per molecule) and, with higher affinity, to fibrinogen (two binding sites per molecule). It did not bind to insolubilized fibrin monomers. The IgG did not impair the catalytic activity of thrombin toward a small synthetic substrate but inhibited the binding of thrombin to fibrinogen without binding to thrombin. The binding of the anti-fibrinopeptide A autoantibody to fibrinogen might have impaired thrombin-induced fibrinogen to fibrin conversion in vivo. This may have favoured the reported haemorrhagic syndrome which was associated with severe chronic renal insufficiency.

    Topics: Autoantibodies; Binding Sites; Blood Coagulation Disorders; Fibrin; Fibrinogen; Fibrinopeptide A; Hemorrhage; Humans; Immunoglobulin G; Kidney Failure, Chronic; Male; Middle Aged; Thrombin

1992
Intraperitoneal heparin in peritoneal dialysis and its effect on fibrinopeptide A in plasma and dialysate.
    Haemostasis, 1989, Volume: 19, Issue:1

    In 6 patients on continuous ambulatory peritoneal dialysis we investigated the inhibition of intraperitoneal fibrin formation by heparin. A continuous addition of 500 U of heparin per liter dialysate was used for 52 h. In plasma no heparin activity could be detected, even 52 h after intraperitoneal administration of heparin. The fibrin formation was determined by fibrinopeptide A, a thrombin-induced split product of fibrinogen. In patients under regular continuous ambulatory peritoneal dialysis we determined the fibrinopeptide A concentrations in plasma. The values were comparable with the fibrinopeptide A concentrations measured in disseminated intravascular coagulopathy. They decreased during intraperitoneal administration of heparin from 63.2 +/- 11.8 to 4.9 +/- 1.7 ng/ml. The fibrinopeptide A concentration in the 4-hour intraperitoneal dialysate (155.8 +/- 15.7 ng/ml) decreased after heparin administration to 8.5 +/- 2.0 ng/ml and was always higher than in plasma. We conclude that 500 U heparin per liter dialysate prevents the intraperitoneal fibrin formation. The low antithrombin III concentration (0.44 +/- 0.13 mg/dl) in protein-poor dialysate seems to be sufficient to inhibit the thrombin activity after acceleration by heparin.

    Topics: Ascitic Fluid; Diabetic Nephropathies; Female; Fibrinogen; Fibrinopeptide A; Heparin; Humans; Kidney Failure, Chronic; Male; Peritoneal Dialysis, Continuous Ambulatory; Solutions

1989
Low molecular weight heparin in haemodialysis for chronic renal failure: dose finding study of CY222.
    Thrombosis and haemostasis, 1988, Apr-08, Volume: 59, Issue:2

    A dose finding study of the very low molecular weight heparin CY222 (MW 2500) in patients (n = 8) with chronic renal failure undergoing dialysis has been carried out to (i) establish an effective dose and (ii) determine the relationship between ex vivo anti-factor Xa levels in plasma and the anticoagulant effect (in vivo suppression of FPA levels). Doses of CY222 were compared to a dose (5000 iu bolus + 1500 iu/hr) of unfractionated heparin (UFH) that has been shown to suppress FPA levels during prolonged (greater than 5 hr) dialysis (Ireland et al., J Lab Clin Med 103, 643, 1984). CY222 given iv in increasing doses produced a dose related increase in anti-factor Xa levels (measured as Institute Choay u/ml, with CY222 itself as standard) and suppression of FPA levels. When given in its highest dose, 20,000 Institute Choay u bolus + 1500 Institute Choay u/hr, there was little effect upon KCCT, FPA levels were statistically indistinguishable from those of the UFH regime (indicating comparable anticoagulant effect), but anti-factor Xa levels (expressed in Institute Choay u/ml) were 2-3 times those of UFH (expressed in iu/ml). All samples were also assayed for anti-factor Xa level against the proposed low MW Heparin Standard. Plasma levels of CY222 were then found to be 2.78 times lower, so that the anti-factor Xa levels of CY222 required to produce comparable anticoagulant effect were then indistinguishable from those of UFH.(ABSTRACT TRUNCATED AT 250 WORDS)

    Topics: beta-Thromboglobulin; Drug Evaluation; Factor Xa; Fibrinopeptide A; Heparin; Heparin, Low-Molecular-Weight; Humans; Kidney Failure, Chronic; Renal Dialysis; Serine Proteinase Inhibitors

1988
A single dose of a low molecular weight heparin fragment for anticoagulation during hemodialysis.
    Clinical nephrology, 1987, Volume: 27, Issue:1

    A low molecular heparin fragment (Fragmin, mol. wt. 4-6000 d), given as a single injection (dose 5000 anti-Xa U), was used as an anticoagulant during hemodialysis in 11 patients. In comparison, our routine heparinization procedure was used; conventional heparin was given as a bolus injection at the start and then as continuous infusion during dialysis to prolong the whole blood activated clotting time (WBACT) 125-175%. Fibrin formation, followed by visual inspection and the measuring of fibrinopeptide A and fibrin monomer concentrations were equally suppressed by the two regimens. WBACT was less prolonged with Fragmin. Anti-Xa activity above 0.39 U/ml was maintained throughout the dialyses with Fragmin. In conclusion a single dose of Fragmin gives sufficient anticoagulation for hemodialysis lasting up to 4 hours.

    Topics: Adult; Aged; Female; Fibrin; Fibrinopeptide A; Heparin; Humans; Kidney Failure, Chronic; Male; Middle Aged; Molecular Weight; Renal Dialysis

1987
The anticoagulant effect of heparinoid Org 10172 during haemodialysis: an objective assessment.
    Thrombosis and haemostasis, 1986, Apr-30, Volume: 55, Issue:2

    The heparinoid of natural origin Org 10172 has anti-factor Xa activity but minimal anti-thrombin activity, and little effect upon broad spectrum assays such as the KCCT in vitro. Its anticoagulant effects have been compared to those of commercial heparin in 7 patients undergoing haemodialysis for chronic renal failure. Commercial heparin was administered in a dose (5,000 iu bolus + 1,500 iu/hour continuous iv infusion) previously shown to inhibit fibrin formation during haemodialysis. This produced mean anti-factor Xa levels in plasma between 0.7-1.0 iu/ml and largely suppressed fibrin formation for 5 h dialysis measured as mean FPA levels in plasma. Administration of Org 10172 as a bolus of 1,350 anti-factor Xa u or 2,000-2,400 anti-factor Xa u produced plasma anti-factor Xa levels of less than 0.5 u/ml and allowed fibrin clot and FPA generation during dialysis. Org 10172 administered as a bolus dose of 4,000-4,800 anti-factor Xa u produced mean anti-factor Xa levels of greater than 0.5 u/ml, allowed dialysis of 6 patients for 5 h and appreciably suppressed FPA generation during dialysis, with little effect on the KCCT. It is concluded that the anti-factor Xa activity of Org 10172 may reflect its ability to inhibit fibrin during dialysis and that single bolus injection of Org 10172 may be a useful alternative method of achieving anticoagulation.

    Topics: Anticoagulants; Chondroitin Sulfates; Dermatan Sulfate; Evaluation Studies as Topic; Factor X; Factor Xa; Fibrinopeptide A; Glycosaminoglycans; Heparin; Heparitin Sulfate; Humans; Injections, Intravenous; Kidney Failure, Chronic; Male; Platelet Aggregation; Renal Dialysis

1986
On the evaluation of heparin and low molecular weight heparin in haemodialysis for chronic renal failure.
    Haemostasis, 1986, Volume: 16 Suppl 2

    Anticoagulation during haemodialysis for chronic renal failure can be assessed by measurement of plasma fibrinopeptide A (FPA) levels as an objective method of monitoring the initial step in fibrin formation, in conjunction with visual inspection of the dialyser circuit for fibrin clot deposition. Employing this approach, unfractionated commercial heparin administered as an intravenous bolus followed by an intravenous maintenance dose (5,000 IU + 1,500 IU/h) was found to suppress almost completely fibrin formation and deposition during prolonged dialysis. Comparison of a low molecular weight heparin, Kabi 2165, revealed that it can inhibit fibrin formation in the extracorporeal circulation, that this property is largely reflected in its anti-factor Xa activity in plasma, and that a useful and effective dose of Kabi 2165 for haemodialysis may be 4,000 anti-factor Xa U intravenous bolus + 750 anti-factor Xa U/h intravenous maintenance infusion. This dose only minimally alters the KCCT and corresponds to approximately 60% of that of unfractionated heparin, which may be important in the long-term use of heparin in these patients.

    Topics: Biological Availability; Drug Administration Schedule; Evaluation Studies as Topic; Factor X; Factor Xa; Fibrinopeptide A; Heparin; Humans; Injections, Intravenous; Injections, Subcutaneous; Kidney Failure, Chronic; Renal Dialysis

1986
Elevated plasma levels of fibrinopeptide A during sickle cell anemia pain crisis--evidence for intravascular coagulation.
    American journal of hematology, 1978, Volume: 5, Issue:3

    Topics: Anemia, Sickle Cell; Disseminated Intravascular Coagulation; Female; Fibrinogen; Fibrinopeptide A; Humans; Kidney Failure, Chronic; Male; Malingering; Pain

1978